Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Image forming apparatus and exposing apparatus

Toshiba Tec

Image forming apparatus and exposing apparatus

Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image-forming apparatus, and…

Mitsubishi Chemical

Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image-forming apparatus, and…


Date/App# patent app List of recent Receptor-related patents
07/23/15
20150205911 
 System and  predicting the immunogenicity of a peptide patent thumbnailSystem and predicting the immunogenicity of a peptide
A system, computer readable storage medium and method of predicting the immunogenicity of a peptide are provided. In certain cases the system includes: a) a model of a peptide, a model of a mhcii protein and a model of a t cell receptor; and b) an executable program for: (i) evaluating the strength of intermolecular interactions of a complex containing the peptide, the mhcii protein and the t cell receptor to provide a score that predicts the immunogenicity of the peptide; and (ii) outputting the score..
Bayer Healthcare Llc


07/23/15
20150205223 
 Image forming apparatus and exposing apparatus patent thumbnailImage forming apparatus and exposing apparatus
An image forming apparatus includes a light scan head having a plurality of led elements disposed along a main-scanning direction of a photoreceptor drum and configured to expose the photoreceptor drum with light, a developing device disposed to face the photoreceptor drum in the main-scanning direction and including a development roller configured to supply a developer to the photoreceptor drum, and a non-uniform density correction unit configured to control an intensity of light emitted from the plurality of led elements of the light scan head based on correction data that corresponds to a tendency pattern of an expected non-uniform image density so as to correct the non-uniform density of an image that is to be formed on a recording medium.. .
Toshiba Tec Kabushiki Kaisha


07/23/15
20150205217 
 Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image-forming apparatus, and triarylamine compound patent thumbnailElectrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image-forming apparatus, and triarylamine compound
The present invention relates to an electrophotographic photoreceptor comprising an electroconductive support and at least a photosensitive layer formed on the support, wherein the photosensitive layer contains a specific charge transport substance.. .
Mitsubishi Chemical Corporation


07/23/15
20150204892 
 Methods and compositions for diagnosis and prognosis of renal injury and renal failure patent thumbnailMethods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of tumor necrosis factor receptor superfamily member 10b, cadherin-16, caspase-9, bcl2 antagonist of cell death, caspase-1, cadherin-1, poly [adp-ribose] polymerase 1, cyclin-dependent kinase inhibitor 1, cadherin-5, myoglobin, apolipoprotein a-ii, mucin-16, carcinoembryonic antigen-related cell adhesion molecule 5, and cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries..
Astute Medical, Inc.


07/23/15
20150204890 
 Microarrays of g protein coupled receptors patent thumbnailMicroarrays of g protein coupled receptors
Microarrays encompassing gpcrs, methods of making such microarrays, and methods of using such microarrays are described.. .
Princeton Institute Of Life Sciences


07/23/15
20150203918 
 Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop) patent thumbnailMutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
This invention is directed to mutated activin a type i receptor proteins (acvr1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated acvr1 in the diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)..
The Trustees Of The University Of Pennsylvania


07/23/15
20150203897 
 Compositions and  measuring and calibrating amplification bias in multiplexed pcr reactions patent thumbnailCompositions and measuring and calibrating amplification bias in multiplexed pcr reactions
Compositions and methods are described for standardizing the dna amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of dna templates that contains rearranged lymphoid cell dna encoding t cell receptors (tcr) or immunoglobulins (ig). The presently disclosed embodiments are useful to overcome undesirable bias in the utilization of a subset of amplification primers, which leads to imprecision in multiplexed n high throughput sequencing of amplification products to quantify unique tcr or ig encoding genomes in a sample.
Adaptive Biotechnologies Corp.


07/23/15
20150203886 
 Method for cloning t cell receptor patent thumbnailMethod for cloning t cell receptor
An object is to provide a tcr closing system that enables not only bias-free analysis of tcr repertoires, but also collection of antigen-specific tcr α/β cdna pairs and evaluation of functions thereof. There is provided a method for producing a gene of t cell receptor (tcr) specific to an antigen a, which comprises 1) the step of stimulating a group of t cells including a t cell specific to an antigen a or one t cell specific to an antigen a under a condition effective for amplification of a tcr gene; 2) the step of identifying a t cell specific to an antigen a among the group of t cells including a t cell specific to the antigen a, and sorting one t cell specific to the antigen a into a vessel; and 3) the step of subjecting the one activated t cell specific to the antigen a in the vessel to pcr to amplify a gene of tcr specific to the antigen a.
National University Corporation University Of Toyama


07/23/15
20150203837 
 Fusion protein for activating rtk signal transmission by means of light, and use thereof patent thumbnailFusion protein for activating rtk signal transmission by means of light, and use thereof
The present invention relates to a fusion protein for reversibly activating rtk signal transmission by means of light and relates to a use thereof, and the invention provides a fusion protein in which a light induced dimer forming protein is coupled to the c-terminal of a receptor tyrosine kinase (rtk) protein or a modified rtk protein which has been modified so as to eliminate a ligand binding site of the rtk protein or ensure that the ligand does not bind.. .
Korea Advanced Institute Of Science And Technology


07/23/15
20150203830 
 Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes patent thumbnailCompositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
The present invention provides peptides and proteins for use in second generation hiv vaccines and as diagnostic tools in the treatment and control of hiv infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an hla epitope-enhanced vaccine.
The Government Of The United States Of America As Represented By The Secretary Of The Departmen Of H


07/23/15
20150203829 

Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk


The present invention concerns an antibody specific for human alk (anaplastic lymphoma kinase), in particular a scfv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma..
Delenex Therapeutics Ag


07/23/15
20150203819 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a mep precursor cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) modulator. In some embodiments the ahr modulator is an ahr antagonist.
Trustees Of Boston University


07/23/15
20150203817 

Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells


A method of expanding tcralpha deficient t-cells by expressing ptalpha or functional variants thereof into said cells, thereby restoring a functional cd3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary t-cells from donors.
Cellectis


07/23/15
20150203585 

Use of dr6 and p75 antagonists to promote survival of cells of the nervous system


The present invention relates to death receptor-6 (dr6) proteins which are members of the tumor necrosis factor (tnf) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for dr6.
Biogen Idec Ma Inc.


07/23/15
20150203579 

Human antibodies to pd-1


The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203575 

Pilr alpha interactions and methods of modifying same


Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed.
Genentech, Inc.


07/23/15
20150203566 

Fgfr1 extracellular domain combination therapies


Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (fgfr1) extracellular domain (ecd) and/or an fgfr1 ecd fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-fu), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an fgfr1 ecd and/or an fgfr1 ecd fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-fu), leucovorin, pemetrexed, and bevacizumab are also provided.
Five Prime Therapeutics, Inc.


07/23/15
20150203556 

Compositions and methods for modulation of il-20 family cytokine activity


Provided herein are compositions comprising one or more agents that inhibit or reduce the activity of il-20. Optionally, the agents further inhibit or reduce the activity of il-24.
The Uab Research Foundation


07/23/15
20150203550 

Ige peptide vaccine


It is intended to provide an ige peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by seq id no: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by seq id no: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a ch3 region in an ige antibody of the animal and thereby blocking the binding of the ige antibody to an ige receptor..
Nippon Zenyaku Kogyo Co., Ltd.


07/23/15
20150203528 

Treatment of prostate cancer


Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer..
Tokai Pharmaceuticals, Inc.


07/23/15
20150203515 

Compounds that are s1p modulating agents and/or atx modulating agents


Compounds of formula (i) can modulate the activity of one or more sip receptors and/or the activity of autotaxin (atx).. .
Biogen Idec Ma Inc.


07/23/15
20150203505 

Indole carboxamide derivative


The present inventors have conducted studies on mt1 and/or mt2 receptor agonists, and have found that an indole carboxamide compound has an mt1 and/or mt2 receptor agonistic action, thereby completing the present invention. The indole carboxamide compound of the present invention has the mt1 and/or mt2 receptor agonistic action as well as a low cns penetration, and therefore, it can be used as an agent for preventing and/or treating urological diseases; in one embodiment, lower urinary tract symptoms; in another embodiment, urine storage symptom, in another embodiment, urinary incontinence; in a still another embodiment, stress urinary incontinence; and the like..

07/23/15
20150203504 

Buprenorphine analogs


Compounds of the invention may be useful for preparing medicaments useful for treating pain, constipation, and other conditions modulated by activity of opioid and orl-1 receptors. Compounds of the invention may be useful for treating conditions such as pain, constipation, and others modulated by activity of opioid and orl-1 receptors..

07/23/15
20150203496 

Aliphatic spirolactam cgrp receptor antagonists


The present invention is directed to aliphatic spirolactam derivatives which are antagonists of cgrp receptors and useful in the treatment or prevention of diseases in which cgrp is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.


07/23/15
20150203495 

Spirocyclic morphinans and their use


And pharmaceutically acceptable salts and solvates thereof, wherein r1a-r5a, y, za are defined as set forth in the specification. The invention is also directed to use of compounds of formula i′-a, and especially compounds of formula i-a, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.

07/23/15
20150203494 

Pyridonemorphinan analogs and biological activity on opioid receptors


And pharmaceutically acceptable salts and solvates thereof, wherein , r1a-r3a, r4, y and za are defined as set forth in the specification. The invention is also directed to use of compounds of formula i-a to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.

07/23/15
20150203493 

Compounds that are s1p modulating agents and/or atx modulating agents


Compounds of formula (i) can modulate the activity of one or more sip receptors and/or the activity of autotaxin (atx).. .
Biogen Idec Ma Inc.


07/23/15
20150203479 

Androgen receptor modulating compounds


The present disclosure relates to compounds of formula (i), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (i), and pharmaceutically acceptable salts thereof..
Orion Corporation


07/23/15
20150203452 

Piperidinium quaternary salts


There are described new 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain..
Chase Pharmaceuticals Corporation


07/23/15
20150202444 

Systems and methods for selective stimulation of nerve fibers in carotid sinus


An example of a system may include at least one electrode for placement on tissue in a carotid sinus region and a stimulator. The stimulator may be configured to use the at least one electrode to deliver neural stimulation to a baroreceptor region or at least one nerve innervating the baroreceptor region in the carotid sinus region to elicit a baroreflex response, and to deliver a blocking stimulation to a carotid body or at least one nerve innervating the carotid body in the carotid sinus region to inhibit a chemoreceptor response, the stimulator configured to simultaneously deliver the neural stimulation and the blocking stimulation..
Cardiac Pacemakers, Inc.


07/23/15
20150202296 

Method for administering glp-1 molecules


The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating glp-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.. .
Emisphere Technologies, Inc.


07/23/15
20150202287 

Combination therapies comprising anti-erbb3 agents


Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a mek/pi3 kinase/akt inhibitor; iv) an effective amount of mm-151; v) an effective amount of an mtor inhibitor; and/or vi) an effective amount of trastuzumab or t-dm 1, and/or combinations thereof; and an effective amount of a 10 bispecific anti-erbb2/anti-erbb3 antibody..
Merrimack Pharmaceuticals, Inc.


07/23/15
20150202284 

Method of making a vaccine


The present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit b cell receptors (bcrs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the bcrs sufficient to form mature bcrs having the identical or substantially identical sequence as the desired antibody.. .
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services


07/23/15
20150202270 

Methods for introducing mannose 6 phosphate and other oligosaccharides onto glycoproteins and applications thereof


Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (msp), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications..
Genzyme Corporation


07/23/15
20150202269 

Aav-mediated gene therapy for rpgr x-linked retinal degeneration


Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (aav) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa gtpase regulator (rpgr gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier..
University Of Florida Research Foundation, Inc.


07/23/15
20150202261 

Methods and compositions for treating antiprogestin-resistant cancers


The invention provides methods, pharmaceutical compositions and kits for treating a subject having a carcinoma that is resistant to an antiprogestin. In particular, the methods comprise increasing the molar amount of progesterone receptor isoform a (pr-a) so that it is greater than that of isoform b (pr-b) and administering a therapeutically effective amount of an antiprogestin to the subject, thereby treating the carcinoma..
Consejo Nacional De Investigaciones Científicas Y Técnicas


07/23/15
20150202259 

Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof


The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University


07/23/15
20150202230 

Lat adapter molecule for enhanced t-cell signaling and use


Lat (linker for activation of t-cells) is a protein involved in signaling through the t-cell receptor (tcr). The invention provides a lat protein including mutations at ubiquitylation sites that result in an increase in stability of lat in stimulated and unstimulated cells, and enhanced signaling through the tcr.
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services


07/23/15
20150202213 

Combinations comprising antimuscarinic agents and corticosteroids


Combinations comprising (a) a corticosteroid and (b) an antagonist of m3 muscarinic receptors which is 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion x, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.. .

07/23/15
20150202198 

Novel cabergoline derivatives


Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, parkinson's disease using the compounds and compositions disclosed herein.
Map Pharmaceuticals, Inc.


07/23/15
20150202194 

Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases


Behavioral pharmacological data with the compound of formula (i), a novel and selective 5ht2a/2c receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing mk-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an mptp primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent.
Acadia Pharmaceuticals Inc.


07/23/15
20150202178 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

07/16/15
20150198619 

Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain


The present invention relates to the crystal structure of the insulin receptor ectodomain in complex with human insulin and to methods of using the crystal and related structural information to identify, design and screen for compounds that interact with or modulate the insulin receptor and insulin receptor signalling.. .
The Walter And Eliza Hall Institute Of Medical Research


07/16/15
20150198328 

Saturated water generating device


A saturated water generating device includes a thermal receptor including a cavity inside, a liquid entrance connected into the cavity of the thermal receptor, a heat source, and a pillar disposed in the cavity of the thermal receptor. The heat source is used to heat the cavity of the thermal receptor.
Taizhou Dajiang Industry Co., Ltd.


07/16/15
20150198067 

Steam power generating system and method thereof


A steam power generating system is provided with a thermal receptor including a cavity inside, an entrance of liquid and an exit of steam connected into the cavity of the thermal receptor, and a heat source wherein the heat source is used to heat the cavity of the thermal receptor; and a saturated water generating device and a saturated water explosive device both disposed inside the cavity of the thermal receptor. The entrance of liquid, the saturated water generating device, the saturated water explosive device, and the exit of steam are connected successively..
Taizhou Dajiang Industry Co., Ltd.


07/16/15
20150197814 

Egfr and kras mutations


The present invention relates to mutations in epidermal growth factor receptor (egfr) and kras and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated egfr gene or mutated egfr protein and/or a mutated kras gene or mutated kras protein in a tumor sample..
Genentech, Inc.


07/16/15
20150197771 

Domain-swap t cell receptors


Disclosed herein are genetically engineered t cell receptors, and methods, vectors, and genetically engineered t cells related to genetically engineered t cell receptors.. .
California Institute Of Technology


07/16/15
20150197756 

Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna


This invention relates to compounds, compositions, and methods useful for reducing ar target rna and protein levels via use of dsrnas, e.g., dicer substrate sirna (dsirna) agents.. .
Dicerna Pharmaceuticals, Inc.


07/16/15
20150197574 

Use of transferrin receptor antagonist for the treatment of thalassemia


The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders. .
Universite Paris Diderot - Paris 7


07/16/15
20150197563 

Notch binding agents and antagonists and methods of use thereof


The present invention relates to notch-binding agents and notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human notch receptor, such as notch2 and/or notch3, and inhibit tumor growth.
Oncomed Pharmaceuticals, Inc.


07/16/15
20150197524 

Organic compounds


1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1h,2h]-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful for the treatment of diseases involving disorders of the dopamine d1 receptor intracellular pathway, such as parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone—signaling pathway, e.g., female sexual dysfunction.. .

07/16/15
20150197521 

Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of p2y1 receptor which may be used as medicaments..
Bristol-myers Squibb Company


07/16/15
20150197520 

Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators


Wherein x, r1, r2, and r3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described..

07/16/15
20150197519 

Inhibitors of the fibroblast growth factor receptor


Described herein are inhibitors of fgfr-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of fgfr-4.. .
Blueprint Medicines Corporation


07/16/15
20150197510 

Arylethynyl derivatives


It has now surprisingly been found that the compounds of general formula i are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5) which show advantageous biochemical-, physicochemical- and pharmacodynamic-properties compared to compounds of prior art.. .

07/16/15
20150197506 

Novel benzopyran compounds, compositions and uses thereof


Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are op-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol, and op-1074, which is (2s)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol. Op-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode.
Olema Pharmaceuticals, Inc.


07/16/15
20150197490 

Crystalline polymorphic forms of an antidiabetic compound


This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included..

07/16/15
20150196673 

Anticancer therapy


A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions..
Stc.unm


07/16/15
20150196656 

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof


Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (igf-1) and variants thereof, epidermal growth factor (egf), and other ligands to the egf receptor, are provided. The fusion proteins further comprise seq id no:1 or other segments having lysine, glutamic acid, or aspartic acid residues.

07/16/15
20150196586 

Polymeric molecular receptors as phosphate sequestrants


Polymers and compositions utilizing such polymers are disclosed for treating hyperphosphatemia and other illnesses associated with elevated serum phosphate levels. Phosphate binding polymers, or a pharmaceutically acceptable salt of the polymers, comprise pendent groups extending from a backbone of the polymer.
Genzyme Corporation


07/16/15
20150196578 

Combination therapy treatment for viral infections


Therapeutics which employ a combination of an antiviral agent and an ep4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza a virus, for example h1n1, h3n2 and h5n1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, “sars”..
Gemmus Pharma, Inc.


07/16/15
20150196540 

Nmda receptor modulators and uses related thereto


This disclosure relates to nmda modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are nr2c subunit-selective nmda potentiators.
Emory University


07/09/15
20150192869 

Organic photoreceptor, and electrophotographic cartridge and electrophotographic imaging apparatus including the same


An organic photoreceptor including a photosensitive layer disposed on an electrically conductive substrate; and a protective layer disposed on the photosensitive layer, wherein the protective layer includes a cured product of a multifunctional acrylic oligomer including a urethane group and a multifunctional curable compound including a dendrimeric structure.. .
Samsung Electronics Co., Ltd.


07/09/15
20150192594 

Fibroblast growth factor receptors as diagnostic markers of acquired sensory neuronopathies


The present invention relates to the diagnosis of acquired sensory neuronopathies (snn), and to the treatment of these disorders.. .
Centre Hospitalier Universitaire De Saint Etienne


07/09/15
20150192548 

Array of resonant sensors utilizing porous receptor materials with varying pore sizes


A sensor array comprises resonant sensors and porous receptor materials arranged on the resonant sensors to absorb or adsorb one or more analytes. The average pore size of the porous receptor materials on the sensors increases systematically from one sensor to the next in the array.
Matrix Sensors, Inc.


07/09/15
20150191729 

Composition comprising material for inhibiting scf or receptor thereof for treating or preventing diseases associated with vascular permeability


The present invention relates to a composition comprising a material for inhibiting stem cell factor (scf) or the receptor thereof for treating or preventing vascular permeability related diseases. Also, the present invention relates to a method for screening for an agent for treating vascular permeability related diseases, comprising the steps of: (a) treating a sample from a patient suspected of having a disease associated with vascular permeability with a candidate material; and (b) comparing the level of expression of the scf or the receptor thereof with that of a control group.
Ajou University Industry-academic Cooperation Foundation


07/09/15
20150191540 

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient


A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising an interleukin-6 (il-6) antagonist, for example an antibody directed against il-6 receptor, an antibody directed against il-6, an antibody directed against gp130, and the like.. .
Chugai Seiyaku Kabushiki Kaisha


07/09/15
20150191534 

Human antibodies to human delta like ligand 4


The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.


07/09/15
20150191532 

Antibody for epitope tagging, hybridoma cell line and uses thereof


There are provided peptide tags derived from bacteriophytochrome (bphp) that is photoreceptor protein of deinococcusradiodurans, an antibody capable of specifically recognizing the peptide tags, hybridoma cell lines capable of producing the antibody, and uses thereof. The novel peptide tag has advantages in that it has a short length and can remove a non-specific reaction of the conventional c-myc tag and flag tag.
Myongi University Industry And Academai Cooperatio Foundation


07/09/15
20150191524 

Engineering t cell receptors


The use of model t cell receptors (tcrs) as scaffolds for in vitro engineering of novel specificities is provided. Tcrs with de novo binding to a specific peptide-major histocompatibility complex (mhc) product can be isolated by: 1) mutagenizing a t cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of tcr mutants with the specific peptide-mhc, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-mhc ligand.
The Board Of Trustees Of The University Of Illinoi


07/09/15
20150191523 

Toll-like receptors


The present invention relates to toll-like receptors, to cells comprising such toll-like receptors, to methods for the detection of immunostimulatory oligodeoxynucleotides wherein such methods use such toll-like receptors, to immunostimulatory oligodeoxynucleotides detected by use of this method, to the use of such immunostimulatory oligodeoxynucleotides in medicine and to vaccines comprising such immunostimulatory oligodeoxynucleotides.. .
Intervet International B.v.


07/09/15
20150191520 

Complement split product c4d for the treatment of inflammatory conditions


The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Medizinische Universität Wien


07/09/15
20150191496 

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


07/09/15
20150191495 

Antidiabetic tricyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


07/09/15
20150191487 

Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists


Or a pharmaceutically acceptable salt thereof, wherein, r1 is optionally substituted tetrazolyl, r2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and r3, r4, r5 and r6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the p2x3 and/or a p2x2/3 receptor antagonist and methods of making the compounds..

07/09/15
20150191466 

Tropomyosin-related kinase (trk) inhibitors


Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation


07/09/15
20150191457 

Bisaryl (thio)morpholine derivatives as s1p modulators


The present invention relates to bisaryl (thio)morpholine derivatives of the formula (i) wherein r1 is an aryl substitutent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-6c)alkyl optionally substituted with one or more fluoro atoms, (1-4c)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4c)alkylamino, —so2-(1-4c)alkyl, —co-(1-4c)alkyl, —co—o-0-(1-4c)alkyl and —nh—co-(1-4c)alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with (1-4c)alkyl, and (8-10c)bicyclic group, bicyclic heterocycle, each optionally substituted with (1-4c)alkyl optionally substituted with one or more fluoro atoms or oxo; a is selected from —co—, —nh—, —o—, —s—, —so— or —so2—; ring structure b optionally contains one nitrogen atom; r2 is h, (1-4c)alkyl optionally substituted with one or more fluoro atoms, (1-4c)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and r3 is (1-4c)alkylene-r6 wherein the alkylene group may be substituted with (ch2)2 to form a cyclopropyl moiety or with one or more halogen atoms, or r3 is (3-6c)cycloalkylene-r5 or —co—ch2—r6, wherein r6 is —oh, —po3h2, —opo3h2, —cooh, —coo(1-4c)alkyl or tetrazol-5-yl; r4 is h or (1-4c)alkyl; r5 is one or more substituents independently selected from h, (1-4c)alkyl or oxo; w is —o—, —s—, —so— or —so2—; or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (1) is not 2-[4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol. The compounds of the invention have affinity to sip receptors and may be used in the treatment, alleviation or prevention of s1p receptor mediated diseases and conditions..
Abbvie B.v.


07/09/15
20150191455 

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


07/09/15
20150191454 

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

07/09/15
20150191452 

Selective nr2b antagonists


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the nr2b receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


07/09/15
20150191435 

Dual-acting imidazole antihypertensive agents


Wherein: ar, r, r2-3, x, and r5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.

07/09/15
20150191431 

N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products


The invention relates to n-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.. .
Bayer Pharma Aktiengesellschaft


07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/09/15
20150190534 

Compounds for use as positron emission imaging agents


The present invention relates generally to compounds according to formula i that bind more specifically to mutated androgen receptors than to the wild type androgen receptors and therefore are useful as imaging agents for positron emission tomography (pet) used in the diagnosis and monitoring of prostate cancer.. .
University Of Bern


07/09/15
20150190529 

Targeting multiple receptors on a cell surface for specific cell targeting


A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease..
The University Of Kansas


07/09/15
20150190523 

Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation


A pharmaceutical composition comprising a phosphatidylcholine-based opioid receptor antagonist formulation, as well as methods of their use and methods of their preparation are provided herein. Such pharmaceutical composition may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well..
The University Of Chicago


07/09/15
20150190480 

Combination products for treating cancer


The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence seq id no: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence seq id no:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence seq id no: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.. .
Cayla


07/09/15
20150190472 

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ace2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation


The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-ii converting enzyme (ace2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide.
Universidad De Chile


07/09/15
20150190462 

Treatment of fungal and/or protist infections


The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a heparan sulphate proteoglycan (hspg) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or preventing the contamination of surfaces or objects with such peptides..
Ai2 Limited


07/09/15
20150190459 

Method of reducing injury to mammalian cells


A method of inhibiting the binding between n-methyl-d-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the nmda receptor or neuronal protein interaction domain that effect said inhibition of the nmda receptor-neuronal protein interaction.
Nono Inc.


07/09/15
20150190432 

Methods and compositions for in vivo induction of pancreatic beta cell formation


Embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. In certain aspects, the methods include the integration of three levels of cellular physiology: metabolism, membrane receptor function, and gene transcription.
The Board Of Regents Of The University Of Texas System


07/09/15
20150190423 

Method of potentiating an antitumor immune response


A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (go) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of tlr-4 (toll-like receptor 4) and tlr-9 (toll-like receptor 9). Differences between autophagy triggered by go and other conventional agonists such as rapamycin have been observed.
National Tsing Hua University


07/09/15
20150190402 

Solid dosage formulations of an orexin receptor antagonists


The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer.
Merck Sharp & Dohme Corp.


07/09/15
20150190399 

New differential-release pharmaceutical composition containing three active principles


This invention relates to a differential release formulation containing an angiotensin-ii receptor antagonist, a calcium channel blocker and a diuretic, wherein the said pharmaceutical composition allows the sequential administration of the active principles in a single dose based on the treatment needs.. .
Landsteiner Scientific S.a. De C.v.


07/09/15
20150190397 

Treatment of cancers expressing p95 erbb2


The truncated erbb2 receptor (p95erbb2) is shown to differ from the full-length erbb2 receptor in its association with other erbb receptors. The truncated receptor preferentially associated with erbb3, whereas full length erbb2 heterodimerizes with 5 either egfr or erbb3.
Glaxosmithkline Llc


07/09/15
20150190369 

Quercetin-3-glucoside and uses thereof


There is described herein a use of quercetin-3-o-β-d-glucoside (q3g) for increasing the amount of cell surface low-density lipoprotein receptor (ldlr) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (pcsk9) secreted by the cell, where the q3g is formulated for administration to the cell, and where the increase in cell surface ldlr and the decrease in secretion of functional pcsk9 is in comparison to the cell not exposed to q3g. The use may optionally include the treatment of a statin.

07/09/15
20150190307 

Methods and devices for treating hypertension


Devices, systems and methods are described which control blood pressure and nervous system activity by stimulating baroreceptors. By selectively and controllably activating baroreceptors and/or nerves, the present invention reduces blood pressure and alters the sympathetic nervous system; thereby minimizing deleterious effects on the heart, vasculature and other organs and tissues.
Sympara Medical, Inc.


07/09/15
20150190101 

Mammography system and method employing offset compression paddles, automatic collimation, and retractable anti-scatter grid


A mammographic imaging system is optimized for use with a single fixed size flat panel digital image receptor. It accommodates compression devices (paddles) of varying sizes, and positions them properly in a field of view of the image receptor.
Hologic, Inc.




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3473

5036

2 - 1 - 111